Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SA-033
- Development stage
- Preclinical
- Lead developer
- Double Bond Pharmaceutical
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intra-arterial
01
Overview
SA-033 is a liver-targeted formulation of doxorubicin developed by Double Bond Pharmaceutical using the company's proprietary BeloGal drug delivery technology. This innovative platform enables organ-specific administration, increasing the concentration of doxorubicin in the liver to enhance efficacy and reduce systemic toxicity commonly associated with chemotherapy. SA-033 is primarily being developed for the treatment of liver cancer, with its targeted delivery aiming to improve therapeutic outcomes and minimize adverse effects. Doxorubicin acts as a DNA topoisomerase II alpha inhibitor.
- Other names
- Doxorubicin BeloGal
02
Targets
TOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on SA-033.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SA-033.